Diplomat Pharmacy (DPLO) PT Cut to $14 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall St futures rise as US, Iran pause hostilities
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Oil prices drop after US, Iran pause fighting over weekend
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Diplomat Provides 2016 Financial Guidance Update
January 9, 2017 6:00 AM ESTFLINT, Mich., Jan. 9, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced updated 2016 financial guidance. The company now expects 2016 revenue and adjusted EBITDA will be at or near the low end of previously announced ranges.
Phil Hagerman, chairman and CEO of Diplomat, commented, "This was a tough year for Diplomat, and as a result of the various industry challenges we faced throughout 2016, we anticipate our full-year financial results to be at or near the low end... More
